Claim Your Author Page
BACKGROUND The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour activity in models of… (More)
4183 Background: Cyclo-oxygenase-2 (COX-2) is upregulated and may play an important pathogenetic role in both PDAC and BTC. The present study was aimed at evaluating the feasibility, toxicity, and… (More)
To explore the different sequence interactions between reversible non-steroidal (anastrozole, ANZ and letrozole, LTZ) and non-reversible steroidal aromatase inhibitors (formestane, FOR and… (More)
4182 Background: Weekly GEM infused over 30 min is considered the standard of care for advanced PDAC and has activity in advanced BTC. However, a fixed dose-rate infusion at the rate of 10 mg/m2/min… (More)
10065Background: Limited data exist on the safety of using targeted agents in pregnant cancer pts. So far, only retrospective studies assessed the prognosis of pts having a pregnancy after prior EB...
574Background: Higher quantity of pretreatment TIL (PT) is associated with improved pCR and EFS in HER2+ early breast cancer (BC). The value of on-treatment TIL is unknown. Methods: The NeoALTTO tr...
The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is a critical signaling pathway downstream of the growth factor receptor tyrosine kinases that regulates cell… (More)
570Background: CT added to H is the treatment of choice in HER2+ early breast cancer (BC) patients (pts). However HER2+ tumors are clinically and biologically heterogeneous and treatment response… (More)